We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Orphan Drug Exclusivity Remains a Priority in 2023, Says FDA Deputy Commissioner
Orphan Drug Exclusivity Remains a Priority in 2023, Says FDA Deputy Commissioner
Reforms in orphan drug exclusivity will see significant movement in 2023, according to Andi Fristedt, the FDA’s deputy commissioner for policy, legislation, and international affairs.